Ematologia
| Direttore Unità Operativa | ||||
|---|---|---|---|---|
 |
BASSAN RENATO |
|||
| Segreteria | ||||
| 041 9657357 ocme.ematoseg@aulss3.veneto.it |
||||
| Dirigenti Sanitari | ||||
| CAROBOLANTE | FRANCESCA | |||
| FRISON | LUCA | |||
| LEONCIN | MATTEO | |||
| MAZZUCCO | MADDALENA | |||
| PASCARELLA | ANNA | |||
| PERALI | GIULIA | |||
| ROCCONI | ROBERTA | |||
| SANCETTA | ROSARIA | |||
| SARPELLON | CLAUDIA | |||
| SCATTOLIN | ANNA MARIA | |||
| SKERT | CRISTINA | |||
| VIERO | PIERA | |||
| . | ||||
| Coordinatori Infermieristici | ||||
| NIERO CRISTINA Day Hospital (ff.) |
041 9657358 | |||
 |
PETTENÒ ANNA | 041 9657363 | ||
| PAVANETTO | MICHELA | Psicologa | ||
| ZANIBELLATO | SILVIA | Biologa | ||
| Coordinatori di ricerca clinica | ||||
| DEGRANDI | ELIANA | 041 9657311 | ||
| SANNICOLÒ | SIMONA | 041 9657074 | ||
Attività dell'Unità Operativa
| Attività svolta (descrizione) |
|---|
| Attività di ricovero, ambulatorio, Day-Hospital. |
| Centri formalmente istituiti |
| Centro Trapianto di Midollo Osseo Autologo e Allogenico |
| Sottolineatura dei punti di eccellenza |
| 1) Settore diagnostico: diagnosi immediata e accurata delle emopatie acute e croniche, tramite valutazione integrata comprendente citomorfologia, citochimica, citofluorimetria e citogenica/genetica, in stretta collaborazione con il gruppo diagnostico ematologico del Laboratorio Analisi. 2) Settore terapeutico: applicazione di protocolli di trattamento innovativi, di prima e seconda linea, per leucemia acute mieloidi e linfoidi, leucemie linfatiche croniche, leucemia mieloide cronica, linfomi a basso ed alto grado di malignità, mielomi e malattie mieloproliferative croniche, promossi dai principali gruppi di ricerca clinica nazionali ed europei/internazionali (NILG/Gruppo Leucemie Nord-Italia, GIMEMA/Grupppo Italiano Emopatie dell'Adulto, EWALL/Gruppo Europeo Leucemia Acuta Linfoblastica, ELN/Gruppo Europeo Leucemie, FIL/ Federazione Italiana Linfomi, GITIL/Gruppo Italiano Terapie Innovative nei Linfomi, GITMO/Gruppo Italiano Trapianto Midollo Osseo). 3) Unità di trapianto di Midollo Osseo Autologo e Allogenico. 4) Tempistica della prima valutazione ematologica: il tempo di attesa per prima visita ematologica è inferiore a 7 giorni lavorativi dal momento della prenotazione. 5) Valutazione e programmazione terapeutica: i nuovi casi con patologia ematologica importante vengono presentati e discussi giornalmente, ed il piano di trattamento definito collegialmente tra il Direttore ed i medici corresponsabili delle diverse patologie. 6) Collaborazioni e consulenze con altro Ospedali del territorio (San Donà di Piave, Chioggia), per una gestione ottimale della patologia ematologica locale. |
Articolazione dell'Unità Operativa |
| Unità Operativa semplice di trapianto di midollo osseo. Sezione di degenza con unità di trattamento intensivo, numero totale posti letto 19 (a breve ampliamento fino a 24 posti letto). Sezione di Day-Hospital ed ambulatori dedicati (Amb. Leucemie, Amb. Trapianto Midollo Osseo, Amb. monitoraggio linfomi/mielomi, Amb. prime visite e urgenze, Amb. patologie ematologiche non neoplastiche). |
Attività scientifica di particolare rilievo |
| Sperimentazione clinica di terapie innovative. Collaborazioni nazionali ed internazionali nell'ambito della ricerca applicata alla terapia con nuovi farmaci. |
Ricerche sanitarie in corso |
| Protocolli terapeutici attivi: 1. Studio di fase IIA sulla fattibilità e l’efficacia di Inotuzumab Ozogamicin (IO) in pazienti adulti con Leucemia Linfoblastica Acuta a cellule B con Malattia Minima Residua positiva prima di un trapianto di cellule staminali ematopoietiche. (ALL2418) 2. Monitoraggio dell’Attività dell’Asparaginasi (AAM) in pazienti adulti con Leucemia Linfoblastica Acuta (LAL). (ALL2518) 3. D-ALBA Front-Line Sequential Treatment of Adult Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients with Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab. (LAL2116) 4. La Leucemia Linfoblastica Acuta dell’adulto in Italia durante la pandemia COVID-19: uno studio CAMPUS ALL. 5. Sustained treatment-free remission in BCR-ABL+ chronic myeloid leukemia: a prospective study comparing Nilotinib versus Imatinib with switch to Nilotinib in absence of optimal response. 6. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Two-Arm, Phase 2 Study of ME-401 in Subjects with Follicular Lymphoma After Failure of Two or More Prior Systemic Therapies. 7. Studio non-interventistico post-autorizzazione sulla sicurezza (‘post-authorization safety study’, PASS) di lenalidomide in pazienti adulti affetti da mieloma multiplo precedentemente non trattati, che non sono idonei al trapianto (“transplant noneligible” \[TNE]) (“TNE NDMM \[mieloma multiplo di nuova diagnosi] PASS di Revlimid®”). 8. Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (Ponatinib 3001) 9. Studio in aperto per valutare l’attività antitumorale e la sicurezza di REGN1979, un anticorpo bispecifico anti-CD20 x anti-CD3, in pazienti con Linfoma Follicolare recidivante o refrattario. 10. Prephase treatment with prednisone +/- Vitamin D supplementation followed by immunochemotherapy in Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL). A randomized, open label, phase III study by Fondazione Italiana Linfomi. 11. Copanlisib in combination with Rituximab-Bendamustine in patients with Relapsed-Refractory Diffuse Large B-cell Lymphoma: a multicentric Phase II trial. 12. A randomized Phase III study to compare arsenic trioxide (ATO) combined to ATRA and idarubicin versus standard ATRA and anthracycline-based chemotherapy (AIDA regimen) for patients with newly diagnosed, high-risk acute promyelocytic leukemia 13. Studio osservazionale ancillare sul trattamento dei pazienti adulti con Leucemia Acuta Linfoblastica Philadelphia positiva successivo alla terapia sequenziale d’esordio con Dasatinib e l’anticorpo monoclonale bispecifico Blinatumomab 14. A Non-interventional, Post-authorization Safety Study of Patients with Relapsed or Refractory Mantle Cell Lymphoma to Further Investigate and Characterize the Association of Lenalidomide With Tumor Flare Reaction and High Tumor Burden 15. Optimizing Ponatinib USe (OPUS). A GIMEMA phase 2 study of the activity and risk profile of ponatinib, 30 mg once daily, in chronic myeloid leukaemia (CML) chronic phase (CP) patients resistant to imatinib. 16. Studio osservazionale retro-prospettico sul rischio di progressione nei pazienti affetti da Leucemia Mieloide Cronica (LMC) in fase cronica eleggibili a sospensione di inibitore tirosin-chinasico (TFR-PRO). 17. Studio in aperto, multicentrico, di Fase IIIb per valutare la sicurezza d’impiego e l’efficacia di midostaurina (PKC412) in pazienti di età uguale o superiore a 18 anni con leucemia mieloide acuta con FLT3-mutato di nuova diagnosi che sono eleggibili alla chemioterapia “7+3” o “5+2”. 18. A randomized phase III study to compare Bortezomib, Melphalan, Prednisone (VMP) with High Dose Melphalan followed by Bortezomib, Lenalidomide, Dexamethasone (VRD) consolidation and Lenalidomide maintenance in patients with newly diagnosed multiple myeloma. 19. National Treatment Program with Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia. 20. A multi-center, open label, uncontrolled, phase 2a clinical trial evaluating the safety and efficacy of the addition of Ibrutinib to Venetoclax through a MRD-guided approach in relapsed/refractory patients with Chronic Lymphocytic Leukemia (CLL). 21. A MULTICENTER, RANDOMIZED, OPEN LABEL PHASE II STUDY OF CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (CCyd) as pre transplant INDUCTION and post transplant consolidation or CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (CRd) as pre transplant INDUCTION and post transplant consolidation or continuous treatment with CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE (12 cycles) without transplant, all followed by MAINTENANCE with LENALIDOMIDE (R) versus LENALIDOMIDE AND CARFILZOMIB (CR) IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS ELEGIBLE FOR AUTOLOGOUS TRANSPLANT. 22. An onLine-pLatform to improve patient-centered care during the COVID-19 pAndemic: a GIMEMA surveillaNce program in hematologiC malignanciEs. 23. Studio di fase 3, randomizzato, in doppio cieco, controllato con placebo di acalabrutinib in combinazione con rituximab, ciclofosfamide, doxorubicina, vincristina e prednisone (R-CHOP) in soggetti di età =65 anni con linfoma diffuso a grandi cellule B non del centro germinativo non trattato in precedenza. 24. Ponatinib for the management of minimal residual disease (MRD) and hematologic relapse in adult Ph+ acute lymphoblastic leukemia (Ph+ ALL) patients. (ALL2620) 25. Studio di fase III per determinare l’impatto di gemtuzumab ozogamicin, in associazione a chemioterapia standard, sui livelli di malattia minima residua, e il ruolo di glasdegib come mantenimento post-trapianto, in pazienti adulti, di età compresa tra 18 e 60 anni, affetti da Leucemia Mieloide Acuta non precedentemente trattata, di nuova diagnosi, a rischio favorevole o intermedio. 26. Prospective and Retrospective Observational evaluation of Real World Outcome of Unfit Patients with Acute Myeloid Leukemia Treated with the Combination Venetoclax plus Hypomethylating Agents, under the Italian Law No.648/96. 27. A phase 3 multicenter, randomized, prospective, open-label trial of ibrutinib monotherapy versus fixed-duration venetoclax plus obinutuzumab versus fixed-duration ibrutinib plus venetoclax in patients with previously untreated chronic lymphocytic leukemia (CLL). 28. Studio multicentrico, retrospettivo, osservazionale sulla terapia di pazienti adulti affetti da Leucemia Linfoblastica Acuta Philadelphia positiva (LAL Ph+) di nuova diagnosi REAL-LIFE CAMPUS ALL Ph+. 29. A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis. 30. Studio di fase II della Fondazione Italiana Linfomi (FIL) per valutare la combinazione di Lenalidomide e Rituximab in prima linea nei pazienti anziani con linfoma diffuso a grandi cellule B classificati fragili secondo la Valutazione Geriatrica Multidimensionale (CGA). Attività scientifica
Pubblicazioni 2012-20202020 Bassan R, Pavoni C, Intermesoli T, Spinelli O, Tosi M, Audisio E, Marmont F, Cattaneo C, Borlenghi E, Cortelazzo S, Cavattoni I, Fumagalli M, Mattei D, Romani C, Cortelezzi A, Fracchiolla N, Ciceri F, Bernardi M, Scattolin AM, Depaoli L, Masciulli A, Oldani E, Rambaldi A. Updated risk-oriented strategy for acute lymphoblastic leukemia in adult patients 18-65 years: NILG ALL 10/07. Blood Cancer J. 2020 Nov 13;10(11):119. Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2020 Oct 22;383(17):1613-1623. Gallamini A, Rossi A, Patti C, Picardi M, Romano A, Cantonetti M, Oppi S, Viviani S, Bolis S, Trentin L, Gini G, Battistini R, Chauvie S, Sorasio R, Pavoni C, Zanotti R, Cimminiello M, Schiavotto C, Viero P, Mulé A, Fallanca F, Ficola U, Tarella C, Guerra L, Rambaldi A. Consolidation Radiotherapy Could Be Safely Omitted in Advanced Hodgkin Lymphoma With Large Nodal Mass in Complete Metabolic Response After ABVD: Final Analysis of the Randomized GITIL/FIL HD0607 Trial. J Clin Oncol. 2020 Sep 18:JCO2000935. doi: 10.1200/JCO.20.00935. Lussana F, Minetto P, Ferrara F, Chiaretti S, Specchia G, Bassan R. National Italian Delphi panel consensus: which measures are indicated to minimize pegylated-asparaginase associated toxicity during treatment of adult acute lymphoblastic leukemia? BMC Cancer. 2020 Oct 2;20(1):956. doi: 10.1186/s12885-020-07461-5. C Caprioli, F Lussana, S Salmoiraghi, R Cavagna, K Buklijas, L Elidi, P Zanghì, A Michelato, F Delaini, E Oldani, T Intermesoli, A Grassi, G Gianfaldoni, F Mannelli, D Ferrero, E Audisio, E Terruzzi, L De Paoli, C Cattaneo, E Borlenghi, I Cavattoni, M Tajana, AM Scattolin, D Mattei, P Corradini, L Campiotti, F Ciceri, M Bernardi, E Todisco, A Cortelezzi, B Falini, C Pavoni, R Bassan, O Spinelli, A Rambaldi. Clinical significance of chromatin-spliceosome acute myeloid leukemia: a report from the Northern Italy Leukemia Group (NILG) randomized trial 02/06. Haematologica.2020Aug27:haematol.2020.252825.doi: 10.3324/haematol.2020.252825. S Salmoiraghi, R Cavagna, ML Guinea Montalvo, G Ubiali, M Tosi, B Peruta, T Intermesoli, E Oldani, A Salvi, C Pavoni, U Giussani, R Bassan, A Rambaldi, O Spinelli. Immature immunoglobulin gene rearrangements are recurrent in B precursor adult Acute Lymphoblastic Leukemia carrying TP53 molecular alterations. Genes. 2020 020 Aug 20;11(9):960. doi: 10.3390/genes11090960. F Passamonti, C Cattaneo, L Arcaini, R Bruna,M Cavo, F Merli, E Angelucci, M Krampera, R Cairoli, MG Della Porta, N Fracchiolla, M Ladetto, C Gambacorti Passerini, M Salvini, M Marchetti, R Lemoli, A Molteni, A Busca, A Cuneo, A Romano, N Giuliani, S Galimberti, A Corso, A Morotti, B Falini, A Billio, F Gherlinzoni, G Visani, MC Tisi, A Tafuri, P Tosi, F Lanza, M Massaia, M Turrini, F Ferrara, C Gurrieri, D Vallisa, M Martelli, E Derenzini, A Guarini, A Conconi, A Cuccari, L Cudillo, D Russo, F Ciambelli, AM Scattolin, M Luppi, C Selleri, E Ortu La Barbera, C Ferrandina, N Di Renzo, A Olivieri, M Bocchia, M Gentile, F Marchesi, P Musto, AB Federici, A Candoni, A Venditti, C Fava, A Pinto, P Galieni, L Rigacci, D Armiento, F Pane, M Oberti, P Zappasodi, C Visco, M Franchi, P Grossi, L Bertù, G Corrao, L Pagano, P Corradini on behalf of the ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020 https://doi.org/10.1016/S2352-3026(20)30251-9. Mannelli F, Gianfaldoni G, Bencini S, Piccini M, Cutini I, Bonetti MI, Scappini B, Pancani F, Ponziani V, Chiarini M, Borlenghi E, Bassan R, Rossi G, Bosi A. Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in AML. Am J Hematol. 2020 Jul 22. doi: 10.1002/ajh.25942. Salmoiraghi S, Cavagna R, Zanghì P, Pavoni C, Michelato A, Buklijas K, Elidi L, Intermesoli T, Lussana F, Oldani E, Caprioli C, Stefanoni P, Gianfaldoni G, Audisio E, Terruzzi E, De Paoli L, Borlenghi E, Cavattoni I, Mattei D, Scattolin A, Tajana M, Ciceri F, Todisco E, Campiotti L, Corradini P, Fracchiolla N, Bassan R, Rambaldi A, Spinelli O. High Throughput Molecular Characterization of Normal Karyotype Acute Myeloid Leukemia in the Context of the Prospective Trial 02/06 of the Northern Italy Leukemia Group (NILG). Cancers (Basel). 2020 Aug 11;12(8):E2242. Visentin A, Nasillo V, Marchetti M, Ferrarini I, Paolini R, Sancetta R, Rigolin GM, Cibien F, Riva M, Briani C, Marinello S, Piazza F, Gherlinzoni F, Krampera M, Bassan R, Cuneo A, Luppi M, Semenzato G, Marasca R, Trentin L. Clinical Characteristics and Outcome of West Nile Virus Infection in Patients with Lymphoid Neoplasms: An Italian Multicentre Study. Hemasphere. 2020 Jun 8;4(3):e395. Cavagna R, Guinea Montalvo ML, Tosi M, Paris M, Pavoni C, Intermesoli T, Bassan R, Mosca A, Rambaldi A, Spinelli O. Capture-based Next-Generation Sequencing Improves the Identification of Immunoglobulin/T-Cell Receptor Clonal Markers and Gene Mutations in Adult Acute Lymphoblastic Leukemia Patients Lacking Molecular Probes. Cancers (Basel). 2020 Jun 9;12(6):1505. Chiaretti S, Messina M, Della Starza I, Piciocchi A, Cafforio L, Cavalli M, Taherinasab A, Ansuinelli M, Elia L, Albertini Petroni G, La Starza R, Canichella M, Lauretti A, Puzzolo MC, Pierini V, Santoro A, Spinelli O, Apicella V, Capria S, Di Raimondo F, De Fabritiis P, Papayannidis C, Candoni A, Cairoli R, Cerrano M, Fracchiolla N, Mattei D, Cattaneo C, Vitale A, Crea E, Fazi P, Mecucci C, Rambaldi A, Guarini A, Bassan R, Foà R. Philadelphia-like acute lymphoblastic leukemia is associated with minimal residual disease persistence and poor outcome. First report of the minimal residual disease-oriented GIMEMA LAL1913. Haematologica.2020May28:haematol.2020.247973.doi: 10.3324/haematol.2020.247973. Epub ahead of print. Soverini S, Albano F, Bassan R, Fabbiano F, Ferrara F, Foà R, Olivieri A, Rambaldi A, Rossi G, Sica S, Specchia G, Venditti A, Barosi G, Pane F. Next-generation sequencing for BCR-ABL1 kinase domain mutations in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A position paper. Cancer Med. 2020 May;9(9):2960-2970. Carobolante F, Chiaretti S, Skert C, Bassan R. Practical guidance for the management of acute lymphoblastic leukemia in the adolescent and young adult population. Ther Adv Hematol. 2020 Feb 3;11:2040620720903531. Gianfaldoni G, Mannelli F, Intermesoli T, Bencini S, Giupponi D, Farina G, Cutini I, Bonetti MI, Masciulli A, Audisio E, Ferrero D, Pavoni C, Scattolin AM, Bosi A, Rambaldi A, Bassan R. Early peripheral clearance of leukemia-associated immunophenotypes in AML: centralized analysis of a randomized trial. Blood Adv. 2020 Jan 28;4(2):301-311. Gökbuget N, Dombret H, Giebel S, Brüggemann M, Doubek M, Foa R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Maria Ribera J, Schoonen M, Tuglus C, Zugmaier G, Bassan R. Blinatumomab vs historic standard-of-care treatment for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukaemia. Eur J Haematol. 2020 Apr;104(4):299-309. Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020 Jun;7(6):e456-e468. Furia S, Nannini N, Pascarella A, Breda C. Mediastinal Rosai-Dorfman Disease With Widespread Lesions: When Surgical Biopsy Is Needed. Ann Thorac Surg. 2020 Jan;109(1):e45-e47. Soverini S, Bavaro L, De Benedittis C, Martelli M, Iurlo A, Orofino N, Sica S, Sorà F, Lunghi F, Ciceri F, Galimberti S, Baratè C, Bonifacio M, Scaffidi L, Castagnetti F, Gugliotta G, Albano F, Russo Rossi AV, Stagno F, di Raimondo F, D'Adda M, di Bona E, Abruzzese E, Binotto G, Sancetta R, Salvucci M, Capodanno I, Girasoli M, Coluzzi S, Attolico I, Musolino C, Calistri E, Annunziata M, Bocchia M, Stella S, Serra A, Errichiello S, Saglio G, Pane F, Vigneri P, Mignone F, Laginestra MA, Pileri SA, Percesepe A, Tenti E, Rosti G, Baccarani M, Cavo M, Martinelli G. Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study. Blood. 2020 Feb 20;135(8):534-541. 2019 Maurillo L, Bassan R, Cascavilla N, Ciceri F. Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease. Cancers (Basel). 2019 Sep 23;11(10):1417. Bassan R, Fumagalli M, Chiaretti S, Audisio E, Cascavilla N, Paolini S, Delia M, Cerqui E, Micò C, Fabbiano F, Canichella M, Scattolin AM, Perfetti P, Paoloni F, Iodice M, Vitale A, Della Starza I, Fazi P, Vignetti M, Foà R. Phase II trial with sequential clofarabine and cyclophosphamide for refractory and relapsed philadelphia-negative adult acute lymphoblastic leukemia. Results of the GIMEMA LAL 1610 protocol. Leuk Lymphoma. 2019 Dec;60(14):3482-3492. Soverini S, Bassan R, Lion T. Treatment and monitoring of Philadelphia chromosome-positive leukemia patients: recent advances and remaining challenges. J Hematol Oncol. 2019 Apr 23;12(1):39. Bassan R, Intermesoli T, Masciulli A, Pavoni C, Boschini C, Gianfaldoni G, Marmont F, Cavattoni I, Mattei D, Terruzzi E, De Paoli L, Cattaneo C, Borlenghi, E, Ciceri F, Bernardi M, Scattolin AM, Todisco E, Campiotti L, Corradini P, Cortelezzi A, Ferrero D, Zanghì P, Oldani E, Spinelli O, Audisio E, Cortelazzo S, Bosi A, Falini B, Pogliani EM, Rambaldi A. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Adv. 2019 Apr 9;3(7):1103-1117. Bassan R, Brüggemann M, Radcliffe HS, Hartfield E, Kreuzbauer G, Wetten S. A systematic literature review and meta-analysis of minimal residual disease as a prognostic indicator in adult B-cell acute lymphoblastic leukemia. Haematologica. 2019 Oct;104(10):2028-2039. Bassan R, Hoelzer D, Thomas X, Montesinos P, Pavlu J, McKendrick J, Kudlac A, Barlev A, Barber B, Cong Z. Clinician Concepts of Cure in Adult Relapsed and Refractory Philadelphia-Negative B Cell Precursor Acute Lymphoblastic Leukemia: A Delphi Study. Adv Ther. 2019 Apr;36(4):870-879. Gökbuget N, Dombret H, Giebel S, Bruggemann M, Doubek M, Foà R, Hoelzer D, Kim C, Martinelli G, Parovichnikova E, Rambaldi A, Ribera JM, Schoonen M, Stieglmaier JM, Zugmaier G, Bassan R. Minimal residual disease level predicts outcome in adults with Ph-negative B-precursor acute lymphoblastic leukemia. Hematology. 2019 Dec;24(1):337-348. Mian M, Pescosta N, Badiali S, Cappelletto PC, Marcheselli L, Luminari S, Patriarca F, Zambello R, Pascarella A, Tagariello G, Marabese A, Mondello P, Billio A, Cortelazzo S. Phase II trial to investigate efficacy and safety of bendamustine, dexamethasone and thalidomide in relapsed or refractory multiple myeloma patients after treatment with lenalidomide and bortezomib. Br J Haematol. 2019 Jun;185(5):944-947. Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Fozza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G. Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Adv. 2019 Dec 23;3(24):4280-4290. 2018 Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S. New Approaches to the Management of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 2018 Dec 10;36(35):3504-3519. Gallamini A, Tarella C, Viviani S, Rossi A, Patti C, Mulé A, Picardi M, Romano A, Cantonetti M, La Nasa G, Trentin L, Bolis S, Rapezzi D, Battistini R, Gottardi D, Gavarotti P, Corradini P, Cimminiello M, Schiavotto C, Parvis G, Zanotti R, Gini G, Ferreri AJM, Viero P, Miglino M, Billio A, Avigdor A, Biggi A, Fallanca F, Ficola U, Gregianin M, Chiaravalloti A, Prosperini G, Bergesio F, Chauvie S, Pavoni C, Gianni AM, Rambaldi A. Early Chemotherapy Intensification With Escalated BEACOPP in Patients With AdvancedStage Hodgkin Lymphoma With a Positive Interim Positron Emission Tomography/Computed Tomography Scan After Two ABVD Cycles: Long-Term Results of the GITIL/FIL HD 0607 Trial. J Clin Oncol. 2018 Feb 10;36(5):454-462. Tiribelli M, Bonifacio M, Binotto G, Iurlo A, Cibien F, Maino E, Guella A, Festini G, Minotto C, De Biasi E, De Marchi F, Scaffidi L, Frison L, Bucelli C, Medeot M, Calistri E, Sancetta R, Stulle M, Orofino N, Krampera M, Gherlinzoni F, Semenzato G, Pizzolo G, Ambrosetti A, Fanin R. Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget. 2018 Feb 12;9(18):14219-14227. Efficace F, Castagnetti F, Martino B, Breccia M, D'Adda M, Angelucci E, Stagno F, Cottone F, Malato A, Trabacchi E, Capalbo SF, Gobbi M, Visani G, Salvucci M, Capodanno I, Tosi P, Tiribelli M, Scortechini AR, Levato L, Maino E, Binotto G, Gugliotta G, Vignetti M, Baccarani M, Rosti G. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib. Cancer. 2018 May 15;124(10):2228-2237. 2017 Bassan R, Intermesoli T, Scattolin A, Viero P, Maino E, Sancetta R, Carobolante F, Gianni F, Stefanoni P, Tosi M, Spinelli O, Rambaldi A. Minimal Residual Disease Assessment and Risk-based Therapy in Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2017 Jul;17S:S2-S9. Bassan R. Selective liver toxicity and therapeutic progress in acute lymphoblastic leukaemia. Lancet Haematol. 2017 Aug;4(8):e346-e347. Patriarca F, Giaccone L, Onida F, Castagna L, Sarina B, Montefusco V, Mussetti A, Mordini N, Maino E, Greco R, Peccatori J, Festuccia M, Zaja F, Volpetti S, Risitano A, Bassan R, Corradini P, Ciceri F, Fanin R, Baccarani M, Rambaldi A, Bonifazi F, Bruno B. New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment? Expert Opin Biol Ther. 2017 Jul;17(7):821-836. Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AM, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017 Mar;102(3):529-540. Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech- Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia. N Engl J Med. 2017 Mar 2;376(9):836-847. 2016 Dozzo M, Carobolante F, Donisi PM, Scattolin A, Maino E, Sancetta R, Viero P, Bassan R. Burkitt lymphoma in adolescents and young adults: management challenges. Adolesc Health Med Ther. 2016 Dec 23;8:11-29. Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J. 2016 Sep 23;6(9):e473. Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, Chia V, Doubek M, Giebel S, Hoelzer D, Ifrah N, Katz A, Kelsh M, Martinelli G, Morgades M, O'Brien S, Rowe JM, Stieglmaier J, Wadleigh M, Kantarjian H. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica. 2016 Dec;101(12):1524-1533. Lussana F, Intermesoli T, Gianni F, Boschini C, Masciulli A, Spinelli O, Oldani E, Tosi M, Grassi A, Parolini M, Audisio E, Cattaneo C, Raimondi R, Angelucci E, Cavattoni IM, Scattolin AM, Cortelezzi A, Mannelli F, Ciceri F, Mattei D, Borlenghi E, Terruzzi E, Romani C, Bassan R, Rambaldi A. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome. Biol Blood Marrow Transplant. 2016 Nov;22(11):1983-1987. Bassan R. Reply to C.S. Hourigan et al. J Clin Oncol. 2016 Jul 20;34(21):2559-60. Rousselot P, Coudé MM, Gokbuget N, Gambacorti Passerini C, Hayette S, Cayuela JM, Huguet F, Leguay T, Chevallier P, Salanoubat C, Bonmati C, Alexis M, Hunault M, Glaisner S, Agape P, Berthou C, Jourdan E, Fernandes J, Sutton L, Banos A, Reman O, Lioure B, Thomas X, Ifrah N, Lafage-Pochitaloff M, Bornand A, Morisset L, Robin V, Pfeifer H, Delannoy A, Ribera J, Bassan R, Delord M, Hoelzer D, Dombret H, Ottmann OG; European Working Group on Adult ALL (EWALL) group. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL. Blood. 2016 Aug 11;128(6):774-82. Hoelzer D, Bassan R, Dombret H, Fielding A, Ribera JM, Buske C; ESMO Guidelines Committee. Acute lymphoblastic leukaemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v69-v82. Maino E, Bonifacio M, Scattolin AM, Bassan R. Immunotherapy approaches to treat adult acute lymphoblastic leukemia. Expert Rev Hematol. 2016 Jun;9(6):563-77. Salmoiraghi S, Montalvo ML, Ubiali G, Tosi M, Peruta B, Zanghi P, Oldani E, Boschini C, Kohlmann A, Bungaro S, Intermesoli T, Terruzzi E, Angelucci E, Cavattoni I, Ciceri F, Bassan R, Rambaldi A, Spinelli O. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival. Haematologica. 2016 Jun;101(6):e245-8. Bassan R, Maino E, Cortelazzo S. Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment. Eur J Haematol. 2016 May;96(5):447-60. Bassan R. Using Minimal Residual Disease to Improve Treatment Response Definitions and Hematopoietic Cell Transplantation Strategy in Acute Leukemia. J Clin Oncol. 2016 Feb 1;34(4):300-2. 2015 Bassan R, Spinelli O. Minimal Residual Disease Monitoring in Adult ALL to Determine Therapy. Curr Hematol Malig Rep. 2015 Jun;10(2):86-95. Bassan R, Masciulli A, Intermesoli T, Audisio E, Rossi G, Pogliani EM,Cassibba V, Mattei D, Romani C, Cortelezzi A, Corti C, Scattolin AM, Spinelli O, Tosi M, Parolini M, Marmont F, Borlenghi E, Fumagalli M, Cortelazzo S, Gallamini A, Marfisi RM, Oldani E, Rambaldi A. Randomized trial of radiation-free central nervous system prophylaxis comparing intrathecal triple therapy with liposomal cytarabine in acute lymphoblastic leukemia. Haematologica. 2015 Jun;100(6):786-93. Piccin A, Steurer M, Mitterer M, Blöchl EM, Marcheselli L, Pusceddu I, Marabese A, Bertozzi I, Corvetta D, Randi ML, Elli E, Pogliani EM, Veneri D, Perbellini O, Krampera M, Pacquola E, Gottardi M, Tiribelli M, Guella A, Innella B, Vivaldi P, De Biasi E, Sancetta R, Rocconi R, Bassan R, Gherlinzoni F, Pizzolo G, Gastl G, Cortelazzo S. Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. Intern Emerg Med. 2015 Jun;10(4):451-60. Maino E, Scattolin AM, Viero P, Sancetta R, Pascarella A, Vespignani M, Bassan R. Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells. Mediterr J Hematol Infect Dis. 2015 Jan 1;7(1):e2015001. Bonifacio M, Binotto G, Maino E, Calistri E, Marin L, Scaffidi L, Frison L, De Marchi F, Krampera M, Semenzato G, Fanin R, Ambrosetti A, Tiribelli M; Gruppo Triveneto LMC. Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica. 2015 Aug;100(8):e299-301. Tiribelli M, Binotto G, Calistri E, Maino E, Scffidi L, Medeot M, Nabergoj M, Ambrosetti A, Semenzato G, Fanin R, Bonifacio M; Gruppo Triveneto LMC. Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. Am J Hematol. 2015 Jul;90(7):E135-7. Rocconi R, Mazzucato S, Farina C, Grandesso S. Severe invasive pulmonary zygomycosis by Rhizomucor pusillus and concomitant severe bacterial endocarditis in acute promyelocytic leukaemia. Infez Med. 2015 Sep;23(3):265-9. 2014 Chiaretti S, Zini G, Bassan R. Diagnosis and subclassification of acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014 Nov 1;6(1):e2014073. Spinelli O, Tosi M, Peruta B, Guinea Montalvo ML, Maino E, Scattolin AM, Parolini M, Viero P, Rambaldi A, Bassan R. Prognostic significance and treatment implications of minimal residual disease studies in Philadelphia-negative adult acute lymphoblastic leukemia. Mediterr J Hematol Infect Dis. 2014 Sep 1;6(1):e2014062. Rohatiner AZ, Smith ML, Spinelli O, Rambaldi A, Bassan R, di Bona E, Rodeghiero F, Raimondi R, Björkholm M, Johnson S, Newland AC, Cavenagh JD, Macdougall F, Waters R, Fitzgibbon J, Barbui T, Lister A. Myeloblative therapy with autologous haematopoietic stem cell support as consolidation of first remission in acute myeloid leukaemia - very long follow-up. Br J Haematol. 2014 Dec;167(5):724-6. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, Borlenghi E, Pogliani EM, Di Bona E, Cassibba V, Scattolin AM, Romani C, Ciceri F, Cortelezzi A, Gianfaldoni G, Mattei D, Audisio E, Rambaldi A. Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia. Blood Cancer J. 2014 Jul 11;4(7):e225. Maino E, Sancetta R, Viero P, Imbergamo S, Scattolin AM, Vespignani M, Bassan R. Current and future management of Ph/BCR-ABL positive ALL. Expert Rev Anticancer Ther. 2014 Jun;14(6):723-40. Bassan R. Ph+ ALL: imatinib grows older with patients. Blood. 2014 Feb 6;123(6):801-3. Parolini M, Mecucci C, Matteucci C, Giussani U, Intermesoli T, Tosi M, Rambaldi A, Bassan R. Highly aggressive T-cell acute lymphoblastic leukemia with t(8;14)(q24;q11): extensive genetic characterization and achievement of early molecular remission and long-term survival in an adult patient. Blood Cancer J. 2014 Jan 17;4(1):e176. Magni M, Di Nicola M, Patti C, Scimè R, Mulè A, Rambaldi A, Intermesoli T, Viero P, Tarella C, Gueli A, Bergui L, Trentin L, Barzan A, Benedetti F, Ambrosetti A, Di Raimondo F, Chiarenza A, Parvis G, Billio A, Attolico I, Olivieri A, Montanari M, Carlo-Stella C, Matteucci P, Devizzi L, Guidetti A, Viviani S, Valagussa P, Gianni AM. Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and RFC in CLL at diagnosis. Bone Marrow Transplant. 2014 Apr;49(4):485-91. Bonifacio M, Binotto G, Calistri E, Maino E, Tiribelli M; Gruppo Triveneto LMC. EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. Ann Hematol. 2014 Jan;93(1):163-4. 2013 Intermesoli T, Rambaldi A, Rossi G, Delaini F, Romani C, Pogliani EM, Pagani C, Angelucci E, Terruzzi E, Levis A, Cassibba V, Mattei D, Gianfaldoni G, Scattolin AM, Di Bona E, Oldani E, Parolini M, Gökbuget N, Bassan R. High cure rates in Burkitt lymphoma and leukemia: a Northern Italy Leukemia Group study of the German short intensive rituximab-chemotherapy program. Haematologica. 2013 Nov;98(11):1718-25. Zaja F, Mian M, Volpetti S, Visco C, Sissa C, Nichele I, Castelli M, Ambrosetti A, Puglisi S, Fanin R, Cortelazzo S, Pizzolo G, Trentin L, Rodeghiero F, Paolini R, Vivaldi P, Sancetta R, Isola M, Semenzato G. Bendamustine in chronic lymphocytic leukemia: outcome according to different clinical and biological prognostic factors in the everyday clinical practice. Am J Hematol. 2013 Nov;88(11):955-60. Tiribelli M, Bonifacio M, Calistri E, Binotto G, Maino E, Marin L, Guardalben E, Branca A, Gherlinzoni F, Semenzato G, Sancetta R, Pizzolo G, Fanin R. EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leuk Res. 2013 Nov;37(11):1457-60. 2012 Bassan R. Toward victory in adult ALL: blinatumomab joins in. Blood. 2012 Dec 20;120(26):5094-5. |
| Prestazioni erogate |
|---|
| Accedi alla lista delle prestazioni |
| Ricovero |
|---|
| Ricoveri programmati su indicazione dei medici competenti di reparto e ambulatorio Ricoveri urgenti su indicazione del Pronto Soccorso e dei Medici del territorio |
| Modalità di ingresso |
| Secondo la normale prassi di accoglimento |
| Trattamento in corsia |
| Sistemazione in stanze ad 1 o 2 letti con bagno privato. |
| Servizi osp. non sanitari |
| Supporto psicologico |
Note - come arrivare
Come arrivare
Come arrivare
| File | Dimensione | Azioni |
|---|---|---|
| Guida ai servizi Ematologia Mestre | 225.02 KB |
Ultimo aggiornamento:
28/12/2021